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Objectives. The aim of the study was to establish whether fecal calprotectin concentration (FCC) may be useful in children with
chronic abdominal pain to differentiate between inflammatory bowel disease (IBD), other inflammatory gastrointestinal disorders,
and functional gastrointestinal disorders. Methods. The study included 163 patients (median age 13 years), who were assigned to
four study groups: group 0 (control), 22 healthy children; group 1, 33 children with functional gastrointestinal disorders; group
2, 71 children with inflammatory gastrointestinal disorders other than IBD; group 3, 37 children with IBD. FCC was measured
using ELISA assay. Results. In group 0 and group 1 FCCs were below 100𝜇g/g. Low FCCs were found in 91% of patients in group 2.
In patients with IBD FCCs were markedly elevated with median value of 1191.5 𝜇g/g. However, in children with inflammatory
gastrointestinal disorders other than IBD and in children with IBD mean FCCs were significantly higher compared with the
control group. Significant differences in FCCs were also found between group 1 and group 2, between group 1 and group 3, and
between group 2 and group 3. Conclusion. FCC is the best parameter allowing for differentiation between IBD, other inflammatory
gastrointestinal disorders, and functional gastrointestinal disorders. High FCC is associated with a high probability of IBD and/or
other inflammatory gastrointestinal disorders, and it allows excluding functional gastrointestinal disorders.
1. Introduction
Chronic abdominal pain in children is a very frequent and
sometimes challenging diagnostic issue. Abdominal pain
may be constant or intermittent of variable severity and
locations. Lack of other features indicative of gastrointestinal
disease makes it difficult to establish a final diagnosis. Dif-
ferential diagnosis of chronic abdominal pain should include
not only disorders of the gastrointestinal system (e.g., gas-
tritis and/or duodenitis, pancreatitis, hepatitis, inflammatory
bowel disease, celiac disease, food allergy, or gastrointestinal
infection) causing inflammatory changes in the gastrointesti-
nal tract, but also diseases of other organs and tissues that are
not related to the gastrointestinal system but are located in
the abdomen (e.g., urinary tract infection, urolithiasis, and
gynecological infections). It is assumed that 14% to 20% of
cases of abdominal pain in children are functional [1]. In
children over one year of age the most frequent functional
gastrointestinal disorders include functional abdominal
pain, functional abdominal pain syndrome, irritable bowel
syndrome, abdominal migraine, and functional dyspepsia
[2].
Patients with functional gastrointestinal disorders
present with various signs and symptoms, which are often
concerning. However, these manifestations have no organic
cause and they require extensive diagnostics based on
clinical criteria, results of physical examination, and key
diagnostic studies. In practice, diagnostics of the functional
disorders is frequently based on exclusion of organic causes,
which implies a more or less invasive approach including
radiological and endoscopic studies. Majority of patients
with chronic and recurrent abdominal pain is unnecessarily
exposed to numerous, time-consuming, expensive, and
frequently stressful diagnostic studies [3]. Avoidance of
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procedures that are often associated with various risks is of
key importance, particularly in the youngest patients.
There is an ongoing search for simple noninvasive tests
that may be used to differentiate between organic and func-
tional gastrointestinal disorders in children. The usefulness
of such tests as lactoferrin, eosinophil cationic protein, nitric
oxide, or mucosal cytokine levels was evaluated in clinical
trials [4–6].
Measurements of fecal calprotectin concentration (FCC)
may be useful in the differential diagnosis of various gastroin-
testinal disorders both in adults and in children [7–15].
Calprotectin is a neutrophil protein that constitutes
approximately 60% of neutrophil cytosol proteins. It belongs
to the S100 family of proteins and has two subunits: the 8 kD
myeloid-related protein 8 (MPR8) and the 14 kD myeloid-
related protein 14 (MPR14). It is also found in macrophages,
monocytes, and eosinophils [16]. Its properties include bind-
ing of calcium and zinc, induction of apoptosis of cancer cells,
and inhibition of growth of bacteria and fungi [17].
Neutrophils that are the key cells forming inflammatory
infiltrates in the gastrointestinal tract do not actively secrete
calprotectin, but they release it in case of cell death or injury
[18].This leads to apoptosis of other cells.The increase in FCC
in persons with gastrointestinal inflammation is thought to
be due to increased numbers of leukocytes in gastrointestinal
mucosa and increasedmigration of neutrophils to the intesti-
nal lumen.
FCC correlates with the extent of neutrophil infiltrates
in intestinal mucosa and with severity of inflammation [7,
19]. Moreover, calprotectin does not undergo enzymatic
degradation or modification by drugs used in therapy. In the
collected specimens calprotectin levels remain stable for as
long as 7 days in ambient temperatures [20].
The usefulness of FCC as a marker of mucosal inflamma-
tion has been proven by several studies and meta-analyses
[21, 22]. Fecal calprotectin is used in the diagnostics of
inflammatory bowel disease (IBD) and particularly of Crohn
disease [23, 24], in monitoring of mucosal healing [25, 26],
and as a prognostic factor in exacerbations of IBD [27].
Results of clinical studies confirm that, in contrast to inflam-
matory diseases, FCC remains low in patients with functional
gastrointestinal disorders [8, 28–30]. Studies assessing the
value of FCC as a screening test in pediatric patients and
particularly those with chronic abdominal pain are limited.
2. Aim of the Study
Theaim of the studywas to establish whether in childrenwith
chronic abdominal pain FCC may be used to differentiate
between IBD, organic inflammatory gastrointestinal disor-
ders other than IBD, and functional gastrointestinal disorders
and therefore to reduce the need for burdensome invasive
diagnostic studies.
3. Patients and Methods
3.1. Patients. We conducted a prospective controlled study of
141 children with chronic abdominal pain who fulfilled the
following inclusion criteria:
(1) Abdominal pain lasting more than 4 weeks with or
without other symptoms, including chronic diarrhea,
constipation, and weight loss.
(2) No prior diagnosis and pharmacological treatment.
(3) Age from 4 to 18 years.
(4) No overt gastrointestinal bleeding and in girls also no
menstrual bleeding within 7 days prior to enrollment.
(5) No concomitant features of acute infection (e.g.,
upper or lower respiratory tract infection).
(6) Informed consent of parents/guardians and informed
consent of a patient over 16 years.
Exclusion criteria were treatment with antibiotics or with
nonsteroidal anti-inflammatory drugs (NSAIDs) in the
month preceding the enrollment.
History of current signs and symptoms and prior treat-
ment was recorded on standardized forms that included
personal identification data, clinical parameters, and 57 ques-
tions concerning symptoms, physiological functions, and
school performance and daily activities.
The control group consisted of children who had no
abdominal painwithin the priormonth, received noNSAIDs,
and in the case of girls hadnomenstrual bleedingwithin prior
7 days.
Patients and their parents/guardianswere informed about
the aim of the study and provided their written consent to
participate.The studywas approved by the Ethical Committee
of the Jagiellonian University.
3.2. Collection of Specimens and the Diagnostic Studies. Fecal
specimens were collected to dedicated containers. Within 15
to 30 minutes of collection they were frozen to −20∘C and
stored until the tests were performed.
Fecal calprotectin was measured with enzyme-linked
immunosorbent assay (ELISA) using PhiCal test (Calpro
AS, Oslo, Norway). The advantages of the assay were its
noninvasive character, stability of calprotectin in ambient
temperature for up to 7 days, and small volumes of samples
necessary to perform the test.
In each patient the following tests were performed:
complete blood count (CBC) with differential blood cell
count, erythrocyte sedimentation rate (ESR), serum elec-
trolyte concentrations, liver function tests (aspartate amino-
transferase, AST, and alanine aminotransferase, ALT), and
kidney function tests (urea, creatinine). In most patients
the following tests were also performed: C-reactive pro-
tein (CRP), endomysial antibodies (EmA), a panel of IBD
antibodies: anti-neutrophil cytoplasmic antibodies (pANCA)
and anti-Saccharomyces cerevisiae antibodies (ASCA), fecal
tumor necrosis factor (TNF) alpha, and fecalmicrobiological,
mycological, and parasitological studies, aswell as fecal occult
blood test and fecal Giardia lamblia antigen assay.
In some children other studies were also performed,
including abdominal ultrasound, lactulose and/or lactose
breath tests, and, when indicated, endoscopic studies with
histological examination of biopsy specimens (gastroscopy
with urease test and/or colonoscopy).
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All the studies were performed at the Department of
Clinical Biochemistry, Pediatric Institute College ofMedicine
Jagiellonian University, Cracow.
3.3. Statistical Analysis. Quantitative studies were compared
using chi-square test and Fisher exact test. Because of sig-
nificantly nonnormal distribution of some of the analyzed
parameters, variance analysis (ANOVA) was used in the
statistical analysis of quantitative variables. Statistical analysis
was performed using the IBM SPSS Statistics 21 software.The
differences were statistically significant if the risk of the Type
I error was below 5% (𝛼 = 0.05).
4. Results
The final analysis included 163 children of a median age of
13 years (25–75 percentile range: 9–16 years). On the basis of
their final diagnosis the patients were assigned to one of the
3 following groups:
(1) Children with functional gastrointestinal disorders
(𝑛 = 33).
(2) Children with inflammatory gastrointestinal disor-
ders other than IBD (𝑛 = 71).
(3) Children with IBD (𝑛 = 37).
The control group (group 0) included 22 healthy children.
In patients assigned to group 1 the diagnosis of functional
gastrointestinal disorders was based on the Rome III criteria
[31]. Group 2 included patients with inflammatory gastroin-
testinal disorders other than IBD, which included esophagi-
tis, gastritis, duodenitis, Helicobacter pylori infection, small
intestinal bacterial overgrowth (SIBO), pancreatitis, or hep-
atitis. Group 3 consisted of patients with IBD diagnosed
according to the Porto criteria [32].
Characteristics of the study population were as fol-
lows: group 0 (control) included 22 children (male/female,
7/15, median age 6.5 years); group 1 included 33 children
(male/female, 23/10, median age 12.5 years); group 2 included
71 children (male/female, 51/20, median age 14 years); and
group 3 included 37 children (male/female, 18/19, median age
14 years).
In all children in the control group and in all patients
with functional gastrointestinal disorders FCC were below
100 𝜇g/g. Moreover, low FCCs were found in 91% of patients
in group 2, whereas in most patients with IBD the FCCs were
markedly above the cutoff value (median level 1191.5𝜇g/g; 25–
75 percentile range: 265.2 𝜇g/g–1684.9 𝜇g/g) (Figure 1).
No significant differences in FCC were found between
the control group and group 1 (𝑝 = 0.744). However, in
children with inflammatory gastrointestinal disorders and
IBDmean FCCs were significantly higher compared with the
control group (𝑝 = 0.019 and 𝑝 < 0.001, resp.). Significant
differences in FCCs were also found between group 1 and
group 2 (𝑝 = 0.031), between group 1 and group 3 (𝑝 <
0.001), and between group 2 and group 3 (𝑝 < 0.001).
Although themedian values in group 1 and group 2 were sim-
ilar (22.15 𝜇g/g versus 32.3 𝜇g/g), 25–75 percentile range in
group 1 (patients with functional gastrointestinal disorders)
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Figure 1: Distribution of fecal calprotectin concentrations (FCC) in
the study groups.
was 19,7 𝜇g/g–29.6 𝜇g/g, compared with 23𝜇g/g–88,7 𝜇g/g in
group 2 (patients with inflammatory gastrointestinal disor-
ders). Statistical analysis (chi-square test) revealed signifi-
cance between group differences (Table 1). Detailed features
of group 2 (patients with inflammatory gastrointestinal disor-
ders other than IBD) with FCC distribution are presented in
Table 2. FCCs in patients with IBD were significantly higher
compared with all other study groups (Table 1 and Figure 1).
Group 3 (patients with IBD) included mostly patients with
ulcerative colitis (UC; 𝑛 = 17) and patients with Crohn
disease (CD; (𝑛 = 15)) but also 5 patients with unclassified
colitis. Median FCC in patients with UC was 1515.0 𝜇g/g, and
25–75 percentile rangewas 456.1–1724.0𝜇g/g.Median FCC in
patients with CD was 1442.0 𝜇g/g and 25–75 percentile range
was 1183.0–1667.2 𝜇g/g. No statistically significant differences
between these groups were found. In patients with IBD no
correlation between the extent of IBD lesions and FCC was
found. In patients with UC no statistically significant differ-
ences between patients with left-sided colitis and pancolitis
were found. In patients with CD no statistically significant
differences between patients with L1, L2, and L3 locations
(based on Paris classification) were found. A significant
positive correlation between UCMayo endoscopic score and
FCC was seen (Spearman test 𝑟 = 0.47; 𝑝 = 0.025).
Patients with new-onset IBD tended to have higher FCC
values than patients with chronic disease (median: 1437 𝜇g/g
versus 634 𝜇g/g; 𝑝 = 0.07).
Sensitivity and specificity of FCC levels >45 𝜇g/g for
the diagnosis of nonfunctional gastrointestinal disorders
were 83.8% and 85.9%, respectively (positive predictive value
[PPV] 0.75; negative predictive value [NPV] 0.91). Assuming
higher FCC (>100 𝜇g/g) as a cutoff point resulted in increased
specificity of the test (90%) but it reduced its sensitivity (78%)
(PPV 0.80; NPV 0.88). Figure 3 presents a receiver operating
curve (ROC) for the difference between patients with and
without IBD.
High TNF alpha concentrations were found in group 3
(median: 19.5 pg/mg, Q1–Q3 range: 6.4–120.8 pg/mg) and in
group 2 (median: 13.85 pg/mg, Q1–Q3 range: 0–32.9 pg/mg)
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Table 1: Comparison of fecal calprotectin concentration (FCC), fecal tumor necrosis factor (TNF) alpha and serumC-reactive protein (CRP)
levels in the study groups.
Group 0 Group 1 Group 2 Group 3
FCC (𝜇g/g)∗; median
(25–75 percentile range) 25.1 (20.7–31.5) 22.15 (19.7–29.6) 32.3 (23–88.7) 1442 (708–1724)
Fecal TNF
alpha∗∗ (pg/100mg of
stool); median (25–75
percentile range)
0.00 (0.00–0.1) 13.85 (0.00–32.9) 19.5 (6.40–120.8)
Serum CRP∗∗∗ (mg/L);
median (25–75 percentile
range)
3.00 (2.97–3.00) 3.00 (3.00–3.19) 3.19 (3.05–9.20)
∗Chi-square test for the variable FCC, 𝑝 < 0.0001.
∗∗Chi-square test for the variable TNF alpha, 𝑝 = 0.0006.
∗∗∗Chi-square test for the variable CRP, 𝑝 = 0.0042.
Table 2: Detailed characterization of Group 2 (patients with inflammatory gastrointestinal disorders other than IBD) with FCC distributions
(𝑛 = 71).
Group 2 MedianFCC (𝜇g/g)
25 percentile
FCC (𝜇g/g)
75 percentile
FCC (𝜇g/g)
Esophagitis/duodenitis/gastritis 36.6 22.0 42,3
Helicobacter pylori gastritis 37.5 28.6 42,3
SIBO 32.8 27.2 40.2
Gastrointestinal infections, for example, EPEC 39.5 39.0 40.4
Other: hepatitis, pancreatitis 33.2 23.0 41.9
FCC distribution is the same for all subgroups (Kruskal-Wallis test for independent groups).
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Figure 2: Distribution of fecal tumor necrosis alpha (TNF alpha)
levels in the study groups.
(Figure 2). These values were significantly higher compared
with other groups. CRP levels weremeasured only in patients
undergoing diagnostic workup of abdominal pain and there-
fore were not assessed in the control group. Comparative
levels of calprotectin, TNF alpha, and CRP in the study
groups are presented in Table 1.
5. Discussion
One of the key diagnostic issues in patients with chronic
abdominal pain is to differentiate between functional and
0
0.2
0.4
0.6
0.8
1
Se
ns
iti
vi
ty
0.2 0.4 0.6 0.8 10
1 − specificity
Figure 3: Receiver operating characteristic (ROC) for fecal calpro-
tectin concentrations.
organic etiology of the symptoms. Diagnostic workup should
focus on a prompt diagnosis of IBD in patients with this
disease, as prolonged diagnostics and lack of appropriate
treatment increase the risk of complications and lead to
delayed growth and puberty in pediatric patients. On the
other hand, numerous unnecessary diagnostic studies should
be avoided in patients with functional disorders.
In our study the diagnosis of IBD was made in 25%
of patients and in approximately half of the participants
abdominal pain had organic causes. In 23% of patients
abdominal pain was caused by functional gastrointestinal
Gastroenterology Research and Practice 5
disorders. In these patients and in the control group lowFCCs
were found.
In the studies published to date various FCC cutoff
points were adopted. Most frequently these were <50 𝜇g/g or
<100 𝜇g/g. Tibble et al. made a diagnosis of irritable bowel
syndrome (IBS) in more than half of the patients consulted
by gastrologists for abdominal pain. They adopted the cutoff
point at 30mg/L (150 𝜇g/g), and sensitivity and specificity of
FCC as a screening test for organic gastrointestinal disorders
were found to be 100% and 97%, respectively [29]. Another
study (Carroccio et al.) revealed that the highest diagnostic
yield for the diagnosis of CD was achieved when the cutoff
point was assumed at 170𝜇g/g.With this cutoff point sensitiv-
ity and specificity of the test were 100% and 95%, respectively.
The authors noted that only one of the 15 children eventually
diagnosed with IBS had FCC > 50𝜇g/g [8]. Other studies
also revealed that adopting FCC cutoff point of 150–160 𝜇g/g
increased specificity of the test with respect to the diagnosis
of IBD [30, 33]. A meta-analysis of 13 studies (including 7
pediatric studies) published by Van Rheenen et al. revealed
that sensitivity and specificity of FCC for the diagnosis of IBD
in pediatric population were lower than in adults and were
93% and 96% versus 92% and 76%, respectively. On the basis
of FCC as a screening test, endoscopy would be performed in
65 instead of 100 children, but such an approach would delay
the diagnosis in 8% of patients [21].The authors adopted FCC
cutoff point at the level of 50 𝜇g/g. Adopting a similar cutoff
value in our study resulted in a slightly lower sensitivity and
higher specificity. Similar to other studies we have confirmed
that high FCCs (>100 𝜇g/g) suggest exclusion of functional
disorders [8]. In our study FCCs > 100 𝜇g/g were not seen
in any of the patients in the control group or patients with
functional gastrointestinal disorders. Adopting higher cutoff
values (>100𝜇g/g) increases specificity, but not sensitivity
of the test. In a small proportion of our patients with IBD
(𝑛 = 7) FCCs were below 100 𝜇g/g. On the other hand, higher
FCCs were also found in some of the patients with other
inflammatory gastrointestinal disorders. This suggests that
FCC is not specific to IBD only and that other inflammatory
gastrointestinal disorders (including SIBO, gastrointestinal
infections, cow milk protein allergy, or celiac disease) may
sometimes cause increased values of this parameter [33–35].
Results of our study demonstrated that FCC has superior
value in the differentiation between functional and inflam-
matory gastrointestinal disorders compared with fecal TNF
alpha and serumCRP levels. However, as FCC is not a perfect
marker, diagnostic procedures must be selected with caution
and decisions to perform further invasive diagnostics should
include data from patient’s history and other diagnostic
studies.
Our study excluded patients with overt gastrointesti-
nal bleeding, as this is one of the “red flag” features
and an indication for endoscopy, as well as patients with
chronic diarrhea. Pediatric patients with chronic abdomi-
nal pain who present no “red flag” features are the most
frequent cause of diagnostic dilemmas for both general
practitioners and gastroenterologists, as they have equivocal
indications of invasive diagnostics. Measurements of FCC
facilitate differentiation between IBD, other inflammatory
gastrointestinal disorders, and functional gastrointestinal
disorders.
In pediatric population and particularly in young chil-
dren, it is very important to reduce the use of invasive diag-
nostic procedures, such as gastroscopy or colonoscopy. High
FCCmay indicate the need for invasive diagnostics, while low
values of this parameter suggest absence of pathologic lesions
in the gastrointestinal mucosa [22].
A study of adult patients revealed that FCC combined
with appropriate indications for endoscopy (according to
the recommendations of EPAGE, European Panel on the
Appropriateness of Gastrointestinal Endoscopy) increased
the chance for successful selection of patients who need
invasive diagnostics. Patients with FCC > 50 𝜇g/g had signifi-
cantly higher incidence of lesions revealed by endoscopy [36].
Unlike commonly used markers of inflammation, such
as ESR, CRP, or elevated leukocyte or platelet counts, FCC
allows for narrowing the search for inflammatory lesions
to the gastrointestinal tract. Therefore it is very useful in
differentiation between functional gastrointestinal disorders
and inflammatory gastrointestinal disorders [8, 21, 28, 30,
37]. The NPV values approaching 90% make it possible to
use FCC as a screening test to exclude organic causes of
abdominal pain in children, thus allowing avoiding further
invasive diagnostics [38, 39].
Additional Points
What Is Known. In adults fecal calprotectin concentration
is a useful marker of inflammatory bowel disease and is
used to monitor activity of the disease. What Is New.
(i) In pediatric patients fecal calprotectin concentrations
over 50 𝜇g/g suggest exclusion of functional gastrointestinal
disorders. (ii) The value of fecal calprotectin as a marker
used for differentiation between functional and inflammatory
gastrointestinal disorders is superior to fecal tumor necrosis
factor alpha and serum C-reactive protein.
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